Search
Hypertension Paid Clinical Trials in South Carolina
A listing of 21 Hypertension clinical trials in South Carolina actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 21
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Herpes Clinical Trial
Recruiting
Help move the future of herpes simplex virus type 2 (HSV-2) genital herpes forward by participating in the Vantage Trial for an investigational vaccine.
Conditions:
HSV-2 Infection
HSV-2
Herpes
Herpes Simplex
Genital Herpes
Genital Herpes Simplex Type 2
HSV-2 Genital Herpes
HIV-1 and HSV-2 Coinfection
Featured Trial
Fronto-Temporal Dementia Research Study
Recruiting
The aim of this study is to better understand the genetics of FTD, in order to
empower researchers with the data they need to potentially identify treatment
options. Help researchers accelerate their understanding of Frontotemporal
Dementia and get access to free, at-home genetic testing and genetic counseling
before and after your test.
empower researchers with the data they need to potentially identify treatment
options. Help researchers accelerate their understanding of Frontotemporal
Dementia and get access to free, at-home genetic testing and genetic counseling
before and after your test.
Conditions:
Frontotemporal Dementia
Alzheimer Dementia
Dementia Alzheimers
Mild Dementia
Dementia
Alzheimer Type
Alzheimer Disease
Dementia of Alzheimer Type
Parkinson's Disease
Parkinson Disease
Idiopathic Parkinson's Disease
ALS
Memory Disorders
Memory Impairment
Memory Loss
Age-Related Memory Disorders
Alzheimer's Disease
Featured Trial
Clinical Research for Alpha-1 Antitrypsin Deficiency–Associated Liver Disease
Recruiting
We’re searching for new treatments for Alpha-1 Liver Disease, but we need your help.
If you
- are between 18 to 75 years of age, inclusive
- Have a confirmed or suspected diagnosis of Alpha-1 Liver Disease
- OR have a family member with a confirmed or suspected diagnosis of Alpha-1
Liver Disease
You may be eligible to participate in a research opportunity evaluating the safety
and effectiveness of an investigational study drug.
If you
- are between 18 to 75 years of age, inclusive
- Have a confirmed or suspected diagnosis of Alpha-1 Liver Disease
- OR have a family member with a confirmed or suspected diagnosis of Alpha-1
Liver Disease
You may be eligible to participate in a research opportunity evaluating the safety
and effectiveness of an investigational study drug.
Conditions:
Crohn's Disease
COPD
Chronic Obstructive Pulmonary Disease (COPD)
Emphysema or COPD
Alpha 1-Antitrypsin Deficiency
AAT Deficiency
AATD
Chronic Obstructive Pulmonary Disease
Emphysema
Pulmonary Emphysema
Bronchiectasis
Panniculitis
Hepatocellular Carcinoma
Cirrhosis
Liver Cirrhosis
Cirrhosis
Liver
Cystic Fibrosis
Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Non-Alcoholic Fatty Liver Disease
Liver Diseases
Liver Disease
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
Recruiting
a Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat (an aldosterone synthase inhibitor), administered on a background of a standardized anti-hypertensive (AHT) medication regimen, in subjects with uncontrolled and/or treatment-resistant hypertension.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/06/2023
Locations: Accelerated Enrollment Solutions (AES)- Anderson, Anderson, South Carolina +2 locations
Conditions: Hypertension
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
Recruiting
The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: AnMed Health, Anderson, South Carolina
Conditions: Pulmonary Arterial Hypertension
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
Recruiting
This prospective study is a multi-center early feasibility study assessing the safety and performance of the Aria CV Pulmonary Hypertension System in patients with pulmonary hypertension and right heart dysfunction.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/04/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension, Right Heart Dysfunction
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation.
Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/04/2023
Locations: AnMed Health Medical Center, Anderson, South Carolina
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: AnMed Health Pulmonary and Sleep Medicine, Anderson, South Carolina
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
Recruiting
A trial to evaluate the safety, tolerability, and functionality of 3P-100, in subjects with Pulmonary Hypertension (PH) accompanying Interstitial Lung Disease (ILD), PH-ILD
Gender:
All
Ages:
Between 22 years and 84 years
Trial Updated:
11/29/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Hypertension, Pulmonary, Lung Diseases, Interstitial
A Study to Test Whether Two Different Doses of BI 685509 Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
Recruiting
This study is open to adults with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver). The purpose of this study is to find out whether a medicine called BI 685509 helps people with this condition.
Participants are put into 3 groups randomly, which means by chance. Participants in 2 groups take different doses of BI 685509 as tablets twice a day. Participants in the placebo group take placebo as tablets twice a day. Placebo tablets look like BI 685509 tab... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/28/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Hypertension, Portal
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
Recruiting
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
11/23/2023
Locations: Research Site, Rock Hill, South Carolina
Conditions: Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)
Recruiting
This is a two-part (Phase 2/Phase 3) study of MK-5475, an inhaled soluble guanylate cyclase stimulator, in participants with pulmonary arterial hypertension (PAH).
The first part (Phase 2) will assess three different doses of MK-5475 compared to placebo in a base period of 12 weeks, followed by comparison of three different doses of MK-5475 during an optional 24 month extension period. The treatment dose with the best efficacy and safety profile in the phase 2 cohort base period will be selecte... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/23/2023
Locations: AnMed Health ( Site 0033), Anderson, South Carolina
Conditions: Pulmonary Arterial Hypertension, Hypertension, Pulmonary
A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12)
Recruiting
This study is being conducted to assess the long-term safety, tolerability, and efficacy of sotatercept (MK-7962, formerly called ACE-011) in participants with Pulmonary Arterial Hypertension (PAH). This open-label, long-term follow-up (LTFU) study is supported by data from the PULSAR study (Phase 2, NCT03496207) in which treatment with sotatercept resulted in hemodynamic and functional improvements in the study participants, including those receiving maximal PAH therapy with double/triple drug... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/23/2023
Locations: Medical University of South Carolina - PPDS ( Site 1003), Mount Pleasant, South Carolina
Conditions: PAH, Pulmonary Arterial Hypertension
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
Recruiting
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) on time to clinical worsening (TTCW) in participants who are newly diagnosed with PAH and are at intermediate or high risk of disease progression.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/23/2023
Locations: Medical University of South Carolina ( Site 1003), Charleston, South Carolina
Conditions: Pulmonary Arterial Hypertension
A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
Recruiting
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus maximum tolerated background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus maximum tolerated background PAH therapy) on time to first event of all cause death, lung transplantation, or PAH worsening-related hospitalization of ≥24 hours, in participants with World Health Organization (WHO) functional class (FC) III or FC IV PAH at high risk of mortality.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/23/2023
Locations: Medical University of South Carolina - PPDS ( Site 1003), Charleston, South Carolina
Conditions: Pulmonary Arterial Hypertension
1 - 12 of 21